NeoStem to Present at Two Upcoming Investor Conferences in March
March 12 2015 - 7:30AM
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a
biopharmaceutical company developing novel cell based personalized
medicine therapies, announced today that the Company's management
will present at the BioCentury Future Leaders in the Biotech
Industry Conference on March 20th and at the Alliance for
Regenerative Medicine Regen Med Investor Day on March 25th.
BioCentury 22nd Annual Future Leaders in the Biotech
Industry
- Date and Time: Friday, March 20, 2015, 1:30 PM
EDT
- Venue: Millennium Broadway Hotel, New York,
New York
- Website:
http://www.biocentury.com/conferences/futureleaders/dates
- Presenter: Dr. David J. Mazzo, Chief Executive
Officer
- Topic: Company Presentation
- Webcast:
www.neostem.com/investors/investor-events/
Alliance for Regenerative Medicine 3rd Annual Regen Med
Investor Day
- Date and Time: Wednesday, March 25, 2015,
11:20 AM EDT
- Venue: Metropolitan Club, New York, New
York
- Website: http://arminvestorday.com/
- Presenter: Dr. David J. Mazzo, Chief Executive
Officer
- Topic: Company Presentation
- Webcast:
www.neostem.com/investors/investor-events/
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation
and enhancement of human health globally through the development of
novel cell based personalized medicine therapeutics that prevent,
treat or cure disease by repairing and replacing damaged or aged
tissue, cells and organs and restoring their normal function. The
combination of a rich therapeutics pipeline and externally
recognized in-house manufacturing expertise has created an
organization with unique capabilities for cost effective and
accelerated product development. www.neostem.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management's current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. Forward-looking statements include
statements herein with respect to the successful execution of the
Company's business strategy, the Company's ability to develop and
grow its business, the successful development of cellular therapies
with respect to the Company's research and development and clinical
evaluation efforts in connection with the Company's Targeted
Immunotherapy Program, Ischemic Repair Program, Immune Modulation
Program and other cell therapies, the future of the regenerative
medicine industry and the role of stem cells and cellular therapy
in that industry, and the performance and planned expansion of the
Company's contract development and manufacturing business as well
as its efforts to expand its capabilities into the cell therapy
tools market. The Company's actual results could differ materially
from those anticipated in these forward-looking statements as a
result of various factors. Factors that could cause future results
to materially differ from the recent results or those projected in
forward-looking statements include the "Risk Factors" described in
the Company's Annual Report on Form 10-K filed with the Securities
and Exchange Commission ("SEC") on March 2, 2015 and in the
Company's other periodic filings with the SEC. The Company's
further development is highly dependent on future medical and
research developments and market acceptance, which is outside of
its control.
CONTACT: NeoStem, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@neostem.com
NeoStem, Inc. (NASDAQ:NBS)
Historical Stock Chart
From Jun 2024 to Jul 2024
NeoStem, Inc. (NASDAQ:NBS)
Historical Stock Chart
From Jul 2023 to Jul 2024